Publications by authors named "Siri Lunde"
The aim of this study was to investigate the prevalence of traumatic experiences and symptoms of posttraumatic stress disorder (PTSD) in treatment-seeking individuals with ongoing substance use disorder (SUD) compared to individuals who have recovered from SUD. Patients with SUD recruited from the STAYER study (N = 114) underwent an examination of alcohol and drug use, childhood trauma, negative life events and PTSD symptomatology. In this study, only participants with 12-month concurrent polysubstance use was included.
View Article and Find Full Text PDFArticle Synopsis
- - Breast cancer remains the most common cancer among women globally, prompting the Prospective Breast Cancer Biobank (PBCB) study to collect blood and urine samples from patients for 11 years to search for new biomarkers that can help detect recurrences at the molecular level.
- - The study involves 1,455 early-stage breast cancer patients providing samples every 6-12 months, and their data will be compared with responses from 200 cancer-free women for a comprehensive analysis of cancer biology and patient outcomes.
- - The PBCB study has received ethical approvals, allowing for comprehensive research and sharing of findings to contribute to global understanding and improvements in breast cancer treatment.
Background: The metabolic consequences of preoperative carbohydrate load in breast cancer patients are not known. The present explorative study investigated the systemic and tumor metabolic changes after preoperative per-oral carbohydrate load and their influence on tumor characteristics and survival.
Methods: The study setting was on university hospital level with primary and secondary care functions in south-west Norway.
Purpose: Tamoxifen is an important targeted endocrine therapy in breast cancer. However, side effects and early discontinuation of tamoxifen remains a barrier for obtaining the improved outcome benefits of long-term tamoxifen treatment. Biomarkers predictive of tamoxifen side effects remain unidentified.
View Article and Find Full Text PDFEndocrine therapy is a key treatment strategy to control or eradicate hormone-responsive breast cancer. However, resistance to endocrine therapy leads to breast cancer relapse. The recent extension of adjuvant tamoxifen treatment up to 10 years actualizes the need for identifying biological markers that may be used to monitor predictors of treatment response.
View Article and Find Full Text PDF